INTRODUCTION: We sought to investigate whether day-night variations occur in the concentration of circulating soluble CD40 ligand in patients with acute coronary syndrome, as this may have practical implications. MATERIALS AND METHODS: We assessed 70 consecutive ST-segment elevation myocardial infarction patients admitted into the Coronary Care Unit and 50 control subjects. Each subject was studied under strictly controlled light/dark conditions. Blood samples were drawn at 09:00 h (light phase) and 02:00 h (dark phase). Nocturnal blood samples were drawn by a trained nurse, with the help of a minute torch with a dim red light in order to avoid any direct lighting on the patient during sleep. The soluble CD40 ligand was measured using a commercially available ELISA. RESULTS: Soluble CD40 ligand levels showed no diurnal variations in control subjects. In the ST-segment elevation myocardial infarction group, however, soluble CD40 ligand concentration (pg/mL) in the light phase was significantly higher than that in the dark phase (167.3+/-63.2 vs 118.9+/-48.3 pg/mL, p<0.001). CONCLUSIONS: The study shows for the first time the existence of diurnal variations in soluble CD40 ligand levels in ST-segment elevation myocardial infarction patients, which indicates the need for standardizing the time of blood sampling for the assessment of this molecule, at least in studies involving ST-segment elevation myocardial infarction patients.
INTRODUCTION: We sought to investigate whether day-night variations occur in the concentration of circulating soluble CD40 ligand in patients with acute coronary syndrome, as this may have practical implications. MATERIALS AND METHODS: We assessed 70 consecutive ST-segment elevation myocardial infarctionpatients admitted into the Coronary Care Unit and 50 control subjects. Each subject was studied under strictly controlled light/dark conditions. Blood samples were drawn at 09:00 h (light phase) and 02:00 h (dark phase). Nocturnal blood samples were drawn by a trained nurse, with the help of a minute torch with a dim red light in order to avoid any direct lighting on the patient during sleep. The soluble CD40 ligand was measured using a commercially available ELISA. RESULTS: Soluble CD40 ligand levels showed no diurnal variations in control subjects. In the ST-segment elevation myocardial infarction group, however, soluble CD40 ligand concentration (pg/mL) in the light phase was significantly higher than that in the dark phase (167.3+/-63.2 vs 118.9+/-48.3 pg/mL, p<0.001). CONCLUSIONS: The study shows for the first time the existence of diurnal variations in soluble CD40 ligand levels in ST-segment elevation myocardial infarctionpatients, which indicates the need for standardizing the time of blood sampling for the assessment of this molecule, at least in studies involving ST-segment elevation myocardial infarctionpatients.
Authors: I Lambrinoudaki; M Karaflou; G Kaparos; O Grigoriou; A Alexandrou; C Panoulis; E Logothetis; M Creatsa; G Christodoulakos; E Kouskouni Journal: J Endocrinol Invest Date: 2010-04-30 Impact factor: 4.256
Authors: Suzanne A B M Aarts; Tom T P Seijkens; Koos J F van Dorst; Christine D Dijkstra; Gijs Kooij; Esther Lutgens Journal: Front Immunol Date: 2017-12-12 Impact factor: 7.561
Authors: Laura A Bosmans; Lena Bosch; Pascal J H Kusters; Esther Lutgens; Tom T P Seijkens Journal: J Cardiovasc Transl Res Date: 2020-03-28 Impact factor: 4.132